


CALCIUM, PARATHYROID HORMONE AND THE CALCITONINS

ROY V. TALMAGE PAUL L. MUNSON

EXCERPTA MEDICA



CALCIUM, PARATHYROID HORMONE AND THE CALCITONINS

PROCEEDINGS OF THE
FOURTH PARATHYROID CONFERENCE

Chapel Hill, N.C., U.S.A., March 15–19, 1971

Editors

ROY V. TALMAGE

PAUL L. MUNSON

Chapel Hill, N.C., U.S.A.



1972

EXCERPTA MEDICA
AMSTERDAM

COPYRIGHT © 1972, EXCERPTA MEDICA

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system, without permission in writing from the publishers.

International Congress Series No. 243

ISBN 90 219 0153 6

EXCERPTA MEDICA OFFICES

<i>Amsterdam</i>	Herengracht 362-364
<i>London</i>	Chandos House, 2 Queen Anne Street
<i>Princeton</i>	Nassau Building, 228 Alexander Street

Printed in The Netherlands by Trio, The Hague

CALCIUM, PARATHYROID HORMONE AND THE CALCITONINS

ORGANIZING COMMITTEE
FOURTH PARATHYROID CONFERENCE

Local Chairman

PAUL L. MUNSON

General Chairman

ROY V. TALMAGE

Members

LEONARD R. BÉLANGER

D. HAROLD COPP

PIETER J. GAILLARD

WILLIAM F. NEUMAN

JOHN A. PARSONS

JOHN T. POTTS JR.

CONTENTS

I. Introduction and summary

R. V. TALMAGE: Introductory remarks	3
P. L. MUNSON: Milestones and new horizons for the endocrinology of calcium and phosphate metabolism	4

II. Comparative biology of the calcitonins

A. D. KENNY: Introductory remarks	9
D. H. COPP, P. G. H. BYFIELD, C. R. KERR, F. NEWSOME, V. WALKER and E. G. WATTS: Calcitonin and ultimobranchial function in fishes and birds	12
D. R. ROBERTSON: Calcitonin in amphibians and the relationship of the paravertebral lime sacs with carbonic anhydrase	21
A. G. E. PEARSE, J. M. POLAK and S. VAN NOORDEN: The neural crest origin of the C cells and their comparative cytochemistry and ultrastructure in the ultimobranchial gland	29
L. F. BÉLANGER and D. H. COPP: The skeletal effects of prolonged calcitonin administration in birds, under various conditions	41
J. D. FEINBLATT and L. G. RAISZ: Secretion of avian ultimobranchial calcitonin in organ culture	51

III. Clinical pathophysiology and pharmacology of the calcitonins

F. C. WILSON: Introductory remarks	55
G. MILHAUD, C. CALMETTES, A. JULIENNE, D. THARAUD, H. BLOCH-MICHEL, J. P. CAVAILLON, R. COLIN and M. S. MOUKHTAR: A new chapter in human pathology: calcitonin disorders and therapeutic use	56
C. Y. C. PAK and F. C. BARTTER: Progress in the study and treatment of osteoporosis	71
I. MACINTYRE, G. V. FOSTER, N. J. Y. WOODHOUSE, P. BORDIER, T. V. GUDMUNDSSON and G. F. JOPLIN: Calcitonin in man	83
F. R. SINGER, H. T. KEUTMANN, R. M. NEER, J. T. POTTS, JR. and S. M. KRANE: Pharmacological effects of salmon calcitonin in man	89
A. H. TASHJIAN, JR., K. E. W. MELVIN, E. F. VOELKEL, B. G. HOWLAND, J. E. ZUCKERMAN and C. MINKIN: Calcitonin in blood, urine and tissue: immunological and biological studies	97
W. J. DUBÉ, R. S. GOLDSMITH, S. B. ARNAUD and C. D. ARNAUD: Hyperparathyroidism secondary to long-term therapy of Paget's disease of bone with calcitonin	113

IV. Chemistry, secretion, and metabolism of calcitonins

C. D. ARNAUD: Introductory remarks	119
J. T. POTTS, JR., H. D. NIALL, H. T. KEUTMANN and R. M. LEQUIN: Chemistry of the calcitonins: species variation plus structure-activity relations, and pharmacologic implications	121
C. W. COOPER, W. H. SCHWESINGER, A. M. MAHGOUN, D. A. ONTJES, T. K. GRAY and P. L. MUNSON: Regulation of secretion of thyrocalcitonin	128
L. J. DEFTOS, T. M. MURRAY, D. POWELL, J. F. HABENER, F. R. SINGER, G. P. MAYER and J. T. POTTS, JR.: Radioimmunoassays for parathyroid hormones and calcitonins	140

J. F. HABENER, F. R. SINGER, R. M. NEER, L. J. DEFTOS and J. T. POTTS, JR.: Metabolism of salmon and porcine calcitonin: an explanation for the increased potency of salmon calcitonin	152
--	-----

V. Chemistry, biosynthesis, secretion and immunoassay of the parathyroid hormone

J. T. POTTS, JR., H. T. KEUTMANN, H. D. NIALI, J. F. HABENER, G. W. TREGGAR, L. J. DEFTOS, J. L. H. O'RIORDAN and G. D. AURBACH: Chemistry of the parathyroid hormones: clinical and physiological implications	159
D. V. COHN, R. R. MACGREGOR, L. L. H. CHU and J. W. HAMILTON: Studies on the biosynthesis <i>in vitro</i> of parathyroid hormone and other calcemic polypeptides of the parathyroid gland	173
L. M. SHERWOOD, M. ABE, J. S. RODMAN, W. B. LUNDBERG, JR. and J. H. TARGOVNIK: Parathyroid hormone: synthesis, storage and secretion	183
R. M. BUCKLE, F. G. SMITH and D. P. ALEXANDER: Assessment of parathyroid glandular activity in the foetus	197
L. R. DUFRESNE and H. J. GITELMAN: A possible role of adenylyl cyclase in the regulation of parathyroid activity by calcium	202
TAI-CHAN PENG and C. W. COOPER: The failure of the parathyroid gland to prevent long-lasting hypocalcemia induced by some anesthetic agents	207
B. L. RIGGS, C. D. ARNAUD and L. H. SMITH: Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to non-parathyroid cancer . .	210
S. B. OLDHAM, J. A. FISCHER, G. W. SIZEMORE and C. D. ARNAUD: Calcium-dependent enzymatic conversion of glandular to secreted parathyroid hormone	213

VI. Intestinal calcium transport

H. F. DeLUCA: The functional metabolism of vitamin D ₃	221
R. BELSEY, H. F. DeLUCA and J. T. POTTS, JR.: Competitive binding assay for vitamin D and 25-OH vitamin D	236
E. B. OLSON, JR., H. F. DeLUCA and J. T. POTTS, JR.: The effect of calcitonin and parathyroid hormone on calcium transport of isolated intestine	240
S. J. BIRGE and H. R. GILBERT: The influence of parathyroid hormone on intestinal Ca transport	247

VII. Relation of parathyroid hormone and calcitonins to renal function and malfunction

P. F. HIRSCH: Introductory remarks	251
I. CLARK and F. RIVERA-CORDERO: The role of the parathyroid glands in the phosphate-induced nephrocalcinosis	253
B. E. C. NORDIN, M. PEACOCK and R. WILKINSON: The relative importance of gut, bone and kidney in the regulation of serum calcium	263
M. GOLDBERG, Z. S. AGUS, J. B. PUSCHETT and D. SENESKY: Mode of phosphaturic action of parathyroid hormone: micropuncture studies	273
O. L. M. BIJVOET, J. VAN DER SLUYS VEER, H. M. GREVEN and A. P. M. SCHELLEKENS: Influence of calcitonin on renal excretion of sodium and calcium	284
H. G. HAAS, M. A. DAMBACHER, J. GUNCAGA and T. LAUFFENBURGER: Effects of calcitonins and parathyroid extract on the kidney. Studies in the hypoparathyroid man	299

VIII. Parathyroid hormone and macromolecules

G. NICHOLS JR.: Introductory remarks	305
P. J. GAILLARD, S. MOSKALEWSKI, M. J. VERHOOG and A. M. WASSENAAR: The influence of parathyroid extract on the secretion of macromolecular material by aggregated chondrocytes <i>in vitro</i>	307
M. OWEN and J. T. TRIFFITT: Plasma glycoproteins and bone	316
C. C. JOHNSTON JR., D. M. SMITH and A. R. SEVERSON: Bone resorption and matrix hexosamine labeling	327
J. P. MACMANUS, T. YOUNDALE, J. F. WHITFIELD and D. J. FRANKS: The mediations by calcium and cyclic AMP of the stimulatory action of parathyroid hormone on thymic lymphocyte proliferation	338

IX. Ultrastructural studies of effects of parathyroid hormone and calcitonins on bone

S. B. DOTY and B. H. SCHOFIELD: Metabolic and structural changes within osteocytes of rat bone	353
M. E. HOLTROP and J. M. WEINGER: Ultrastructural evidence for a transport system in bone	365
J. L. MATTHEWS, J. H. MARTIN, E. J. COLLINS, J. W. KENNEDY III and E. L. POWELL, JR.: Immediate changes in the ultrastructure of bone cells following thyrocalcitonin administration	375
D. M. KALLIO, P. R. GARANT and C. MINKIN: Evidence for an ultrastructural effect of calcitonin on osteoclasts in tissue culture	383

X. Significance of the effects of parathyroid hormone and the calcitonins on bone

W. F. NEUMAN: The bone: blood equilibrium: a possible system for its study <i>in vitro</i>	389
J. A. PARSONS and C. J. ROBINSON: The earliest effects of parathyroid hormone and calcitonin on blood-bone calcium distribution	399
J. W. KENNEDY III and R. V. TALMAGE: Effects of thyrocalcitonin on bone phosphate without concurrent effects on calcium	407
R. A. MEYER JR. and R. V. TALMAGE: Effects of parathyroid hormone on bone calcium without concurrent effects on phosphate	416
R. V. TALMAGE: Further studies on the control of calcium homeostasis by parathyroid hormone	422
W. S. S. JEE, W. E. ROBERTS, H. Z. PARK, G. JULIAN and M. KRAMER: Interrelated effects of glucocorticoid and parathyroid hormone upon bone remodeling	430
R. G. G. RUSSELL, R. MÜHLBAUER, D. A. WILLIAMS, J. REYNOLDS, B. MORGAN, H. COPP and H. FLEISCH: Differences between the effects of calcitonin and of diphosphonates on bone resorption induced by parathyroid hormone in tissue culture and on the osteoporosis of immobilization in rats	440

XI. Tissue culture and *in vitro* studies on bone

G. NICHOLS JR.: Introductory remarks	445
L. G. RAISZ, J. A. WENER, C. L. TRUMMEL, J. D. FEINBLATT and W. Y. W. AU: Induction, inhibition and escape as phenomena of bone resorption	446
J. J. REYNOLDS: A sensitive <i>in vivo/in vitro</i> method for studying substances that influence the resorption of bone	454

M. P. M. HERRMANN-ERLEE, J. G. VAN ZUYLEN and J. W. HEKKELMAN: Studies on the interrelationships of various parathyroid hormone effects on embryonic bone <i>in vitro</i>	463
E. F. VOELKEL, A. H. TASHJIAN JR. and P. GOLDHABER: A non-peptide factor produced by fibrosarcoma cells that stimulates bone resorption in organ culture . . .	478

XII. Mechanisms of intracellular calcium exchange

W. F. NEUMAN: Introductory remarks	483
A. B. BORLE: Parathyroid hormone and cell calcium	484
H. RASMUSSEN, K. KUROKAWA, J. MASON and D. B. P. GOODMAN: Cyclic AMP, calcium and cell activation	492
G. D. AURBACH, R. MARCUS, J. N. M. HEERSCHE, R. N. WINICKOFF and S. J. MARX: Cyclic nucleotides in the action of native and synthetic parathyroid and calcitonin peptides	502
J. N. M. HEERSCHE and G. D. AURBACH: Cyclic AMP response in bone after prolonged exposure to parathyroid hormone	511

XIII. Research standards for parathyroid hormone

C. J. ROBINSON, I. BERRYMAN and J. A. PARSONS: Research standard for bovine PTH: summary of an international collaborative study	515
Cumulated bibliography	519
Subject index	551
Index of authors	559

I. Introduction and summary

INTRODUCTORY REMARKS

ROY V. TALMAGE

The papers which make up this book are those which were presented at the Fourth Parathyroid Conference held in Chapel Hill, N.C., U.S.A., March 15-19, 1971. Previous conferences were held in Montreal, Canada (1967), Leiden, Holland (1964), and Houston, Texas (1960). Following the pattern of previous conferences, the 250 participants who attended this meeting included scientists from many parts of Europe, North and South America, Australia and Japan.

Since the authors of these reports are well recognized for their work in their particular fields related to calcium metabolism, the editors have attempted to retain as far as possible the individual styles of the authors.

The primary function of this book is to present to the reader the latest data and theories relating to the structure, function, biochemistry and metabolism of the two primary hormones controlling calcium metabolism and bone physiology, namely parathyroid hormone and the mammalian calcitonin, thyrocalcitonin. It is not surprising, therefore, that conflicting theories and ideas can be found in the various reports included in this book. It is hoped that this book will stimulate further work and aid in the solution of these differences.

In regard to format, the book has been divided into sections, only as a matter of convenience to the reader, with each section preceded by a short introduction. The placement of many papers is arbitrary since much of the material is overlapping. To make the bibliography more useful, all the references have also been combined into a single list at the end.

It is a pleasure to acknowledge support for the Conference and therefore for this book. Major thanks are expressed to two U.S. governmental agencies, the National Institutes of Health and the Atomic Energy Commission who provided grants in support of the Conference. We also wish to acknowledge the support of the School of Medicine of the University of North Carolina and that of its Department of Pharmacology and Division of Orthopaedic Surgery which hosted the Conference. Credit is also due to the many universities and granting agencies which provided travel funds for the participants.

We would also like to express our appreciation to the following organizations which made direct gifts toward the support of the Conference:

Armour Pharmaceutical Company
The Kroc Foundation
Eli Lilly and Company
N.V. Organon
Schering Corporation
Wilson Laboratories

In the final analysis, the success of the Conference and of this book depends to the greatest extent on the scientists who participated in it, and those who provided the manuscripts for this publication. The editors sincerely appreciate their contributions and their efforts, for it is upon these that the value of this publication rests.

MILESTONES AND NEW HORIZONS FOR THE ENDOCRINOLOGY OF CALCIUM AND PHOSPHATE METABOLISM

PAUL L. MUNSON

Advances in knowledge about parathyroid hormone and the calcitonins since the Third Parathyroid Conference three and a half years ago, many of them reported for the first time at this meeting, have been extraordinary both in number and quality. In this brief summary of the Fourth Parathyroid Conference it would be impossible to do justice to all the excellent science that has been reported here and only a brief outline without mentioning any of the contributors by name has been attempted.

To start with the chemistry of the hormones. The amino acid sequences of 7 of the calcitonins are now known and 3 forms of the hormone have already been synthesized in the organic chemistry laboratory. The similarities in structure are readily apparent and suggest features of the molecule that are essential for biological activity. All forms of the hormone polypeptide contain 32 amino acids. The C-terminal proline amide and the disulfide ring also are common to all the calcitonins. The differences in sequence are striking; more than half of the sequences can be changed without any obvious qualitative alteration in biological effects. The much higher specific activity of salmon ultimobranchial calcitonin and its longer duration of action, apparently due in part to its biological stability, are remarkable. All these varied structures are active in every mammalian species in which they have been tested. Thus far, attempts to discover an active core of the polypeptide or to identify a fragment of the molecule that retains biological activity have been unsuccessful. This is a goal for the future. Even more recently, the entire amino acid sequence of bovine parathyroid hormone has been determined. It also is a single-chain polypeptide, but in its native form, at least as isolated from gland extracts, it is much longer, being comprised of a total of 84 amino acid residues. The amino acid sequence of porcine parathyroid hormone has also just been worked out and found to be quite similar to the bovine hormone. The structure of human parathyroid hormone is not yet known, but it appears to be chemically similar but not identical to bovine and porcine parathyroid hormones. Fortunately, as has been known for a long time, the bovine hormone is active in man. Of special interest is the fact that only a relatively small portion of the molecule at the amino terminus is essential for biological activity; the active 1-34 polypeptide has already been synthesized chemically. Unlike the thyrocalcitonins, where there is essentially no immunological cross-reactivity between human and animal hormones, there is sufficient immunochemical similarity between bovine and human parathyroid hormone to make radioimmunoassay of the hormone feasible in man. A related new development of importance is the identification of simpler compounds that, like pentagastrin, stimulate the natural secretion of endogenous thyrocalcitonin or, like imidazole, appear to mimic the effect of thyrocalcitonin on bone.

Advances in knowledge of vitamin D (a hormone as well as a vitamin) and its metabolites have been just as meteoric as for parathyroid hormone and thyrocalcitonin. The identification

of several metabolites of vitamin D that are as active or more active than vitamin D *in vivo* and, unlike vitamin D itself, are also active *in vitro* has been an exciting new development. These discoveries and particularly the indication that the various D metabolites may serve differential functions and possess different pharmacological spectra have important implications for therapy. The mechanism of action of the vitamin D metabolites in facilitating absorption of calcium from the gastrointestinal tract has been further elucidated, although there remain areas of disagreement. End-product inhibition of vitamin D metabolism is another new discovery of significance.

The radioimmunoassay method for parathyroid hormone has undergone further clarification and improvement and analogous methods for the thyrocalcitonins have also recently been developed. It has been made clear at this meeting that these potentially very valuable methods for the basic research laboratory as well as the clinic still need further refinement and understanding before they become suitable for general use. Current investigations of the radioimmunoassay for human thyrocalcitonin have not yet taken it out of the controversial area and the resolution of remaining problems will be important for deciding a fundamental question: is thyrocalcitonin a normal human hormone? Apparently this is not certain yet.

The chemical and biological characterization of salmon ultimobranchial calcitonin represents a particularly important advance. The high relative potency and extended duration of action in man have made it the form of the hormone of choice in the treatment of Paget's disease of bone for which it has been uniformly found to be effective in a number of different clinical centers. The therapeutic usefulness of thyrocalcitonin for other human disorders is still a matter of interest and investigation. In spite of optimistic reports from at least one group of clinics the general attitude still seems to be one of skepticism concerning the use of thyrocalcitonin in the treatment of osteoporosis. Much additional preliminary investigation will be required before full-scale clinical trials would be justified. From what is known about the pharmacological properties of thyrocalcitonin the use of thyrocalcitonin in this disorder seems so logical that I take a rather optimistic view about the future of thyrocalcitonin in osteoporosis. Another promising area for clinical investigation is the relation of thyrocalcitonin to disorders of calcium metabolism that are secondary to chronic renal failure. One might think that this hormone would be useful in the treatment of this type of secondary hyperparathyroidism as well as others. It is not clear to me why thyrocalcitonin has not found more widespread use in the treatment of primary hyperparathyroidism and other forms of hypercalcemia. Use of the hormone in the prevention of nephrocalcinosis and kidney stones in susceptible patients would also seem to be logical and deserves further investigation.

Medullary thyroid carcinoma is the most thoroughly explored disease involving excess production of thyrocalcitonin. Here it is interesting that the toxic effects of this excess production of the hormone are not more serious. However, there are reports in increasing number of secondary hyperparathyroidism associated with this syndrome. Ectopic production of thyrocalcitonin paralleling production of other polypeptide hormones by non-endocrine tumors, long anticipated, is now beginning to be reported. At the Third Parathyroid Conference, evidence was presented identifying the cell of origin of thyrocalcitonin as the parafollicular or C cell in the thyroid gland and as its analogue in the ultimobranchial body. There is new evidence that this cell is of neural crest origin.

It has long been known that the kidney and the gastrointestinal tract as well as bone are target tissues for parathyroid hormone and vitamin D. The fact that thyrocalcitonin can produce hypocalcemia in the absence of the kidney and the gastrointestinal tract tended earlier to obscure these target tissues as important in its overall action. We now recognize that thyrocalcitonin can stimulate the renal excretion of sodium, calcium, and phosphate, at least under certain circumstances and in certain species, including man. Whether these particular renal effects of thyrocalcitonin are produced by endogenous physiological levels of thyrocalcitonin is still not entirely clear. The mechanism of the parathyroid hormone

effect on phosphate excretion, particularly the interaction of this effect with that on renal handling of sodium, has now been clarified and we may look forward to a similar clarification of the parathyroid hormone effect on calcium excretion. The mechanism of action of vitamin D metabolites on absorption of calcium by the gastrointestinal tract is being investigated very actively. The relative importance of the effect of vitamin D on the calcium-binding protein and on a specialized ATPase will certainly be sorted out by the time of the next Parathyroid Conference.

Factors affecting the biosynthesis of parathyroid hormone, an important subject which previously had received little attention, are now being illuminated by study of the subject in feasible *in vitro* systems. The question of a pro-parathyroid hormone different from the one that has been isolated and chemically characterized from glandular extracts has been raised and the possibility that the secreted form is chemically different from the extracted form is being considered. There is also good evidence that in addition to the secreted form of the hormone various fragments of parathyroid hormone circulate in the blood, some of them reacting in the radioimmunoassay even though they do not possess biological activity. Very likely there are others of both larger and smaller molecular weight than the extracted hormone that are biologically active whether or not they react in a specific immunoassay system. The study of the biosynthesis of thyrocalcitonin appears to be a project for the future.

The mechanisms of action of parathyroid hormone and thyrocalcitonin on bone are also receiving much attention. It is clear that cyclic AMP is an important mediator in the action of parathyroid hormone on bone as well as in kidney. The participation of cyclic AMP in the mechanism of action of thyrocalcitonin has now been more clearly demonstrated and sorting out the complexities of the participation of this mediator for both hormones on the same tissue will be a real challenge. The role of certain prostaglandins in the effect of the two hormones on bone is also now being investigated with some initial positive results. The phenomena of induction and escape relating to the effect of thyrocalcitonin on bone have been well worked out in *in vitro* systems and the correlation of these facts with the action of the hormone *in vivo* will be of great interest. New studies of the ultrastructural effects of parathyroid hormone and thyrocalcitonin are also being reported. In relation to the various cell types that are susceptible to the action of these two hormones, correlation of the ultra-microscopic observations with biochemical phenomena certainly will further our understanding of mechanisms in the future.

The control of secretion of thyrocalcitonin and the related subject of the physiological importance of this hormone are still not settled. The capacity of thyrocalcitonin to protect against hypercalcemia needs further experimentation before we can be sure that this is a true physiological function of the hormone. Under certain circumstances thyrocalcitonin protects against hypercalcemia during the intestinal absorption of calcium of dietary origin. The role of gastrin or other gastrointestinal hormones in mediating the thyrocalcitonin response is a new and interesting complication in the study of control of secretion of the hormone. What was the evolutionary rationale for the original emergence of the calcitonins? The function of calcitonin in fish and in birds, where it originated on the evolutionary scale, is still a mystery.

The Fourth Parathyroid Conference was distinguished, but it was by no means unique among its predecessors, for the number and quality of new unifying hypotheses and theories that were advanced, attacked, and defended. Along with the multitude of new facts brought to light, these generalizations and speculations were responsible for the enthusiasm shown by all participants in the Conference that now, through this publication, can be shared with a wider audience.

II. Comparative biology of the calcitonins

